Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
97 participants
OBSERVATIONAL
2010-04-30
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients.
NCT00275717
Studies of Kidney Transplant Outcome
NCT01277770
Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer
NCT02843763
Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation
NCT05890430
Immune Monitoring and Assay Development in Organ Transplant Recipients
NCT01283295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SIGAL study aims to characterize the immune responses of lymphopenic patients (after administration of ATG) in order to identify possible similarities with immunosenescence.The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATG group
Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
Blood sample
A blood sample is performed one year after kidney transplantation.
anti-CD25 group
Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
Blood sample
A blood sample is performed one year after kidney transplantation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
A blood sample is performed one year after kidney transplantation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signature of informed consent
* Patient who are waiting renal transplant
Exclusion Criteria
* Any history in the last 2 years of immunosuppressive therapy (except steroids)
* History of cancer (except skin cancer) or treated hematological malignancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jamal Bamoulid, Doctor
Role: PRINCIPAL_INVESTIGATOR
CHU Besançon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Besançon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
API/2010/15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.